OBJECTIVE: To evaluate the impact on mortality of standard Schwarz measles immunisation before 9 months of age. DESIGN: Children vaccinated in 1980-3 at 4-5, 6-8, and 9-11 months of age were followed to migration, death, or the age of 5 years. SETTING: One urban district and nine villages in two rural areas of Guinea-Bissau. SUBJECT: 307 children vaccinated at 4-8 months and 256 at 9-11 months. MAIN OUTCOME MEASURES: Mortality from 9 months to 5 years of age for children immunised at 4-5, 6-8, and 9-11 months. RESULTS: Mortality was significantly lower in children vaccinated at 6-8 months than at 9-11 months (mortality ratio = 0.63, (95% confidence interval 0.41 to 0.97), p = 0.047). As vaccination was provided in semiannual or annual campaigns it is unlikely that age at vaccination reflected a selection bias. The trend was the same in all three study areas. Improved survival after early immunisation was not related to better protection against measles infection. With a Cox multivariate regression model to adjust for age, sex, season at risk, season at birth, measles infection, and region, children vaccinated at 4-8 months had a mortality ratio of 0.61 (0.40 to 0.92, p = 0.020) compared with children vaccinated at 9-11 months. Reimmunised children tended to have lower mortality than children who received only one vaccine (0.59 (0.28 to 1.27, p = 0.176)). CONCLUSION: Standard measles vaccination before 9 months is not associated with higher childhood mortality than is the currently recommended strategy of immunising from 9 months, and it may reduce mortality. This has implications for measles immunisation strategy in developing countries.
OBJECTIVE: To evaluate the impact on mortality of standard Schwarz measles immunisation before 9 months of age. DESIGN:Children vaccinated in 1980-3 at 4-5, 6-8, and 9-11 months of age were followed to migration, death, or the age of 5 years. SETTING: One urban district and nine villages in two rural areas of Guinea-Bissau. SUBJECT: 307 children vaccinated at 4-8 months and 256 at 9-11 months. MAIN OUTCOME MEASURES: Mortality from 9 months to 5 years of age for children immunised at 4-5, 6-8, and 9-11 months. RESULTS: Mortality was significantly lower in children vaccinated at 6-8 months than at 9-11 months (mortality ratio = 0.63, (95% confidence interval 0.41 to 0.97), p = 0.047). As vaccination was provided in semiannual or annual campaigns it is unlikely that age at vaccination reflected a selection bias. The trend was the same in all three study areas. Improved survival after early immunisation was not related to better protection against measles infection. With a Cox multivariate regression model to adjust for age, sex, season at risk, season at birth, measles infection, and region, children vaccinated at 4-8 months had a mortality ratio of 0.61 (0.40 to 0.92, p = 0.020) compared with children vaccinated at 9-11 months. Reimmunised children tended to have lower mortality than children who received only one vaccine (0.59 (0.28 to 1.27, p = 0.176)). CONCLUSION: Standard measles vaccination before 9 months is not associated with higher childhood mortality than is the currently recommended strategy of immunising from 9 months, and it may reduce mortality. This has implications for measles immunisation strategy in developing countries.
Entities:
Keywords:
Africa; Africa South Of The Sahara; Age Factors; Child Mortality--changes; Child Survival; Comparative Studies; Delivery Of Health Care; Demographic Factors; Developing Countries; Diseases; Guinea-bissau; Health; Health Services; Immunization; Length Of Life; Longitudinal Studies; Measles--prevention and control; Mortality; Population; Population Characteristics; Population Dynamics; Portuguese Speaking Africa; Primary Health Care; Research Methodology; Research Report; Rural Population; Studies; Survivorship; Urban Population; Vaccination; Viral Diseases; Western Africa
Authors: P Aaby; K Knudsen; T G Jensen; J Thårup; A Poulsen; M Sodemann; M C da Silva; H Whittle Journal: J Infect Dis Date: 1990-11 Impact factor: 5.226
Authors: L E Markowitz; J Sepulveda; J L Diaz-Ortega; J L Valdespino; P Albrecht; E R Zell; J Stewart; M L Zarate; R H Bernier Journal: N Engl J Med Date: 1990-03-01 Impact factor: 91.245
Authors: P Aaby; K Knudsen; H Whittle; I M Lisse; J Thaarup; A Poulsen; M Sodemann; M Jakobsen; L Brink; U Gansted Journal: J Pediatr Date: 1993-06 Impact factor: 4.406
Authors: P Aaby; I M Lisse; H Whittle; K Knudsen; J Thaarup; A Poulsen; M Sodemann; M Jakobsen; L Brink; U Gansted Journal: Epidemiol Infect Date: 1994-04 Impact factor: 2.451
Authors: Peter Aaby; Cesário L Martins; May-Lill Garly; Carlito Balé; Andreas Andersen; Amabelia Rodrigues; Henrik Ravn; Ida M Lisse; Christine S Benn; Hilton C Whittle Journal: BMJ Date: 2010-11-30